The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene (I)
Stock and Other Ownership Interests - Celgene
A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).
 
Michael S. Gordon
Stock and Other Ownership Interests - Caremission; WCCT Global
Consulting or Advisory Role - Castle Biosciences; Deciphera; RedHill Biopharma; TRACON Pharma
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); BeiGene (Inst); BiolineRx (Inst); Calithera Biosciences (Inst); CanBas (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Hengrui Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); SynDevRx (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Merck Serono; Pfizer; Roche; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); CanBas (Inst); Cellceutix (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Merck Serono; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology; Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
 
John Sarantopoulos
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Fulgent Genetics; Genentech/Roche; Merck; Novartis; Pfizer; Sun Pharma; Takeda
 
Dejan Juric
Consulting or Advisory Role - Eisai; EMD Serono; Novartis
 
Brian Lu
No Relationships to Disclose
 
Peng Chen
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Jamie Connarn
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene
 
Yvan Le Bruchec
Employment - Celgene
Stock and Other Ownership Interests - Celgene (I)
 
R. Donald Harvey
Research Funding - Celgene (Inst)